Factor XIa Inhibitors Market Global Report 2026

The factor xia inhibitors market size has grown rapidly in recent years. It will grow from $1.06 billion in 2025 to $1.24 billion in 2026 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to growing prevalence of thromboembolic disorders, increasing incidence of atrial fibrillation, rising limitations associated with conventional anticoagulants, expanding investments in anticoagulation drug research, increasing awareness of stroke prevention strategies.

The factor xia inhibitors market size is expected to see rapid growth in the next few years. It will grow to $2.32 billion in 2030 at a compound annual growth rate (CAGR) of 17%. The growth in the forecast period can be attributed to advancing commercialization of novel factor xia inhibitors, growing demand for safer anticoagulation therapies, increasing regulatory approvals for next generation anticoagulants, expanding adoption across emerging healthcare markets, rising utilization of personalized thrombosis management approaches. Major trends in the forecast period include increasing development of precision targeted factor xia inhibition therapies, growing adoption of oral factor xia inhibitors for long term anticoagulation, rising clinical focus on reducing bleeding risk in thrombosis management, expansion of factor xia inhibitor clinical trials across multiple indications, increasing integration of combination anticoagulant treatment strategies.

The rising burden of thrombotic conditions is expected to propel the growth of the factor XIa inhibitors market going forward. Thrombotic disorders refer to medical conditions in which abnormal blood clots form inside blood vessels, disrupting normal blood flow. The burden of thrombotic conditions is increasing due to an aging population, as older individuals are more susceptible to reduced blood flow, vascular damage, and underlying conditions that elevate the risk of abnormal clot formation. Factor XIa inhibitors support the management of thrombotic disorders by selectively blocking the intrinsic coagulation pathway to prevent pathological clot formation while preserving normal hemostasis, thereby reducing thrombosis risk with a lower tendency for bleeding. For instance, in December 2025, according to the National Health Service (NHS) England, a UK-based government department, venous thromboembolism (VTE) risk assessment coverage in England reached 92% in quarter 3 (October to December 2025) of 2025/26, with 3.4 million out of 3.7 million admitted patients being assessed on admission. Therefore, the rising prevalence of thrombotic disorders is driving the growth of the factor XIa inhibitors market.

Major companies operating in the factor XIa inhibitors market are focusing on developing innovative anticoagulant therapies such as oral FXIa anticoagulants to reduce the risk of thrombotic events while minimizing bleeding complications associated with conventional blood thinners. Oral FXIa anticoagulants are blood-thinning medications taken orally that selectively inhibit Factor XIa (FXIa), an enzyme in the coagulation pathway, helping prevent harmful blood clots such as stroke or heart attack while reducing the risk of excessive bleeding compared to traditional anticoagulants. For instance, in May 2023, Johnson & Johnson, a US-based healthcare company, received U.S. Food and Drug Administration Fast Track Designation for milvexian, an investigational oral factor XIa (FXIa) inhibitor being developed to prevent blood clot formation while potentially reducing the risk of bleeding compared to conventional anticoagulants, thereby supporting improved treatment outcomes in patients with cardiovascular and thromboembolic disorders. The therapy works by selectively inhibiting Factor XIa in the intrinsic coagulation pathway, a key driver of pathological thrombosis, while largely preserving normal hemostatic function, which differentiates it from traditional anticoagulants that affect multiple coagulation factors and are associated with higher bleeding risks.

In September 2025, Cadrenal Therapeutics Inc., a US-based biopharmaceutical company, acquired the Factor XIa inhibitor portfolio of eXIthera Pharmaceuticals for an undisclosed amount. With this acquisition, Cadrenal Therapeutics aims to strengthen its anticoagulation pipeline by expanding into next-generation Factor XIa inhibitors, enhancing its capabilities in both acute and chronic thrombosis management and addressing significant unmet needs in the global anticoagulation market. eXIthera Pharmaceuticals LLC is a US-based biopharmaceutical company specializing in investigational intravenous and oral Factor XIa inhibitors designed for acute care and long-term prevention of thrombotic conditions.

Major companies operating in the factor xia inhibitors market are Johnson & Johnson; Bayer Aktiengesellschaft; Pfizer Inc.; Merck & Co. Inc.; AstraZeneca plc; Bristol-Myers Squibb Company; Sanofi S.A.; Novartis; Takeda Pharmaceutical Co. Ltd.; Regeneron Pharmaceuticals Inc.; Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Ono Pharmaceutical Co. Ltd.; Ionis Pharmaceuticals Inc.; CRISPR Therapeutics; Anthos Therapeutics; Sirius Therapeutics Inc.; Cadrenal Therapeutics Inc.

North America was the largest region in the Factor XIa inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xia inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the factor xia inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The factor XIa inhibitors market consists of sales of antisense oligonucleotides, anticoagulant therapies and other biologic and non-biologic anticoagulant therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services such as drug development, formulation support, and manufacturing services provided by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The factor xia inhibitors market research report is one of a series of new reports that provides factor xia inhibitors market statistics, including factor xia inhibitors industry global market size, regional shares, competitors with a factor xia inhibitors market share, detailed factor xia inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the factor xia inhibitors industry. This factor xia inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.